During development of the vertebrate vascular system essential signals are transduced via protein-tyrosine phosphorylation. Null-mutations of receptor-tyrosine kinase (RTK) genes expressed in endothelial cells (ECs) display early lethal vascular phenotypes. We aimed to identify endothelial protein-tyrosine phosphatases (PTPs), which should have similar importance in EC-biology. A murine receptor-type PTP was identi®ed by a degenerated PCR cloning approach from endothelial cells (VE-PTP). By in situ hybridization this phosphatase was found to be speci®cally expressed in vascular ECs throughout mouse development. In experiments using GST-fusion proteins, as well as in transient transfections, trapping mutants of VE-PTP co-precipitated with the Angiopoietin receptor Tie-2, but not with the Vascular Endothelial Growth Factor receptor 2 (VEGFR-2/Flk-1). In addition, VE-PTP dephosphorylates Tie-2 but not VEGFR-2. We conclude that VE-PTP is a Tie-2 speci®c phosphatase expressed in ECs, and VE-PTP phosphatase activity serves to speci®cally modulate Angiopoietin/Tie-2 function. Based on its potential role as a regulator of blood vessel morphogenesis and maintainance, VE-PTP is a candidate gene for inherited vascular malformations similar to the Tie-2 gene.
Keywords: receptor-type tyrosine phosphatase; vascular endothelium; Tie-2; interaction Protein tyrosine-phosphorylation is a key mechanism in endothelial cell proliferation and dierentiation processes since RTK activity is a prerequisite for vasculogenesis and angiogenesis (reviewed in Hanahan, 1997; Risau, 1997) . EC-speci®c RTKs are regulated by a complex array of secreted ligands (Korpelainen and Alitalo, 1998) of dierent and even antagonistic activity (Asahara et al., 1998; Maisonpierre et al., 1997; Suri et al., 1996) . We reasoned that EC-speci®c PTPs are likely to play an important role in balancing signaling from and in resensitization of RTKs. Therefore, we performed a PCR-screen of a murine brain capillary cDNA library and reverse transcribed mRNA of bEND5 endothelioma cells to identify endothelial speci®c members of the protein-tyrosine phosphatase family (Streuli, 1996) . Degenerated primers were derived from highly conserved protein sequences in the catalytic PTP domain (Figure 1a ). Nearly 50% of the obtained cDNA fragments (Table 1) corresponded to the same cDNA species speci®cally expressed in vascular endothelial cells (Figure 3) , Vascular Endothelial-PTP (VE-PTP). A database search identi®ed the previously described receptor-type PTP human protein-tyrosine-phosphatase b (HPTPb) (Krueger et al., 1990) , which is distinct from human and mouse RPTPb/PTPz, as a homologue of VE-PTP (Figure 1b) . Together with Dep-1, VE-PTP belongs to the unique subclass III of receptor-type PTPs bearing exclusively ®bronectin type III-like repeats in the extracellular domain and a single catalytic domain in the cytoplasmic tail ( Figure 1a ) (Brady-Kalnay and Tonks, 1995) . Northern blot analysis of VE-PTP expression revealed a major transcript of approximately 11 kb and two additional transcripts of 7.5 and 6 kb. In the adult mouse VE-PTP mRNA was strongly expressed in brain as well as in lung and heart. Very weak expression was detectable in kidney ( Figure 2a ). These data were con®rmed by semi-quantitative RT ± PCR performed with RNA from mouse organs. Low levels of VE-PTP transcript were also detected in testis and liver. During embryonic development VE-PTP was weakly expressed at embryonic day E11, expression increased at E15 reaching a maximum at E17 ( Figure  2b ). Strong expression was detected at E7, which may result from expression in contaminating maternal tissue as expression in the placenta was observed by in situ hybridization analysis as well (data not shown).
These data led us to perform a closer analysis of the in vivo expression of VE-PTP mRNA by in situ hybridization to frozen sections of mouse embryonic tissues. At the earliest time point analysed (E9.5), expression was detectable in the endothelial cell layer lining the dorsal aortae (data not shown). During the subsequent developmental stages VE-PTP expression was increased throughout the developing vascular system (Figure 3a) . Strong hybridization signals were visible in endothelial cells forming blood vessels, whereas no speci®c signals were detected in blood cells or smooth muscle cells surrounding the vessels (Figure 3b and c) . At E15.5 speci®c signals were detectable in all organs with highest expression in the lung (Figure 3d and e). Comparison to serial sections hybridized with an antisense probe to VEGFR-2 (Flk-1) as an endothelial cell marker (Millauer et al., 1993) , con®rmed the vascular endothelial speci®c expression pattern of VE-PTP (Figure 3f and g ). In contrast to the uniform expression levels of VEGFR-2 in dierent types of embryonic ECs, VE-PTP was more strongly expressed in endothelial cells lining larger, smooth 
were used in 50 ml PCR reactions. As templates 1.25 mg of l-DNA from mouse P4-10 brain capillary-library (SchnuÈ rch and or 3 ml of SuperScript cDNA preparation (GIBCO ± BRL) from bEND5 mRNA were used. Isolated 370 bp products were cloned into the pCRII vector (Invitrogen), analysed by restriction analysis and sequenced on an ABI 370 automated sequencer (Applied Biosystems). (b) Primary protein sequence alignment of VE-PTP with its human homologue HPTP b and PrPTPbrev 5'-GGCCGGTCCCTACGAATGCTGAGCCGG-GCAG-3' deduced from a partial clone for`mRPTPb' (Schepens et al., 1992) cloned in pBS (Stratagene), and chicken b-actin cDNA fragment (Ikeda et al., 1995) were labeled with a 32 P-dCTP (rediprime, Amersham Pharmacia Biotech). For Northern blot analysis 20 mg of total RNA from mouse tissues (Chomczynski and Sacchi, 1987) were loaded to a formaldehyde containing agarose gel and blotted. A mouse embryonic mRNA Northern blot was obtained from Clontech and hybridization was carried out according to the manufacturer's instructions. Autoradiography was performed at 7708C for 17 days. For semiquantitative PCR 50 ml reactions containing 2 ml of reverse transcribed cDNA preparations and 20 pmol of primers betaseq2 5'-CCCTCTCCCTTCCTACCTGG-3' and betarev 5'-GGCCGGTCCCTACGAATGCTGAGCCGGG-CAG-3' were used, giving a 416 bp fragment. Thirty cycles PCR was optimized to detect 1 fg of VE-PTP plasmid DNA. b-actin RT ± PCR was performed as described (Nakajima-Iijima et al., 1985) muscle cell invested vessels than those of small capillaries and veins. On brain sections of newborn mice, speci®c expression of VE-PTP was detectable in brain capillaries as well as in larger vessels (Figure 3h ±  k) . No speci®c signals were visible in neuronal or glial cells.
We next investigated the potential interaction of VE-PTP with the EC-speci®c RTKs Tie-2 and VEGFR-2 using bacterial GST-fusion proteins. In mixing experiments of EC lysates and trapping mutants of the VE-PTP catalytic domain (Flint et al., 1997) fused to GST, we detected interaction with the Tie-2 receptor, while GST alone did not precipitate Tie-2. The interaction was independent of EC-pretreatment with pervanadate. In these assays coprecipitation of VEGFR-2 was never detectable (Figure 4a ). In pull-down experiments using GST-fusion proteins of the catalytic domain of wildtype (wt) VE-PTP as well as the C/S and R/A trapping mutants from lysates of COS-1 cells transiently transfected with EC-RTKs-expression plasmids, we observed an association of the Tie-2-receptor with wt GST-VE-PTP protein as well as with the trapping mutants. After stripping and reprobing the membrane with an a-phosphotyrosine speci®c antibody (Ab) the Tie-2 receptor precipitated with the trapping mutants revealed a considerably higher level of phosphorylation compared to Tie-2 receptor interacting with wt VE-PTP (Figure 4b) . Pretreatment of cells with pervanadate increased the overall tyrosine phosphorylation of the Tie-2 receptor but did not alter the binding ability of Tie-2 to either wt VE-PTP or to the trapping mutants.
To test for potential substrate interactions with Tie-2 and VEGFR-2, we co-expressed these RTKs with either a FLAG-tagged version of VE-PTP corresponding to aa 1418-1997 of HPTPb, or the respective trapping mutants (Figure 1a) . Physical association was analysed by co-immunoprecipitation using an a-FLAG-antibody and subsequent blotting of the precipitates with Abs speci®c for the respective RTK. FLAG-tagged wt VE-PTP was at a reproducibly lower level expressed than its trapping mutants when checked In situ hybridization: As templates for in vitro transcription pCRII VE-PTPpart1 (370 bp fragment of VE-PTP coding for protein sequence corresponding to aa 1786 ± 1913 in HPTPb (Krueger et al., 1990) in pCRII (Invitrogen)) and pBS VE-PTPpart2 were used. Sectioning of mouse embryos and in situ hybridization were performed as described (Breier et al., 1992) by blotting with an a-FLAG-antibody. At the same time, we detected signi®cantly large numbers of dying transfected COS-1 cells evaluated by co-expression of green¯uorscent protein (GFP) in these transfections. In this assay the Tie-2 receptor co-precipitated with both trapping mutants of VE-PTP (C/S, R/A) and to a lesser extend with wt VE-PTP (Figure 4c ), which might re¯ect the lower expression level of wt VE-PTP. Unlike Tie-2, VEGFR-2 could neither be co-immunoprecipitated with VE-PTP nor with either of the trapping mutants, even though VEGFR-2 expression was comparable to that of Tie-2 (data not shown).
Finally, we determined the phosphorylation state of the RTKs in the presence of VE-PTP. In total lysates of COS-1 cells Tie-2 receptor co-expressed with wt VE-PTP showed a markedly reduced level of tyrosine phosphorylation than with the catalytically impaired C/S mutant (data not shown). Subsequently immunoprecipitates of VEGFR-2 and Tie-2 co-expressed with either the wt VE-PTP or VE-PTP trapping mutants (C/S, R/A) were blotted with an a-phosphotyrosinespeci®c Ab and then reprobed with Abs speci®c for the RTK. Only for Tie-2, changes in the phosphorylation status were observed (Figure 5a ). In the presence of the trapping mutants (C/S, R/A) the receptor was reproducibly more highly phosphorylated than in the controls. This hyperphosphorylation of Tie-2 in the presence of catalytically impaired trapping mutants suggests that physical interaction leads to protection of the receptor from dephosphorylation. In contrast, hypophosphorylation of the Tie-2 receptor was observed in the presence of wt VE-PTP, when pervanadate pretreatment of bEND5 cells; tot. lys.: total lysates) Precipitates were blotted with a-Tie-2 Ab and reblotted with VEGFR-2 speci®c Ab (b) GST and GST6VE-PTP derivatives were incubated with lysates of COS-1 cells transfected with Tie-2 expression plasmid. Precipitates were blotted with a-Tie-2 Ab and reblotted with a-phosphotyrosine speci®c Ab. Methods: GSTfusion preparation and pull-down experiments: pGEX-VE-PTP contains a 1.1 kB 3' part of EST-clone 552065 (Lennon et al., 1996) coding for the cytoplasmic domain of VE-PTP cloned in pGEX 3T (Amersham Pharmacia Biotech). GST and GST-fusion proteins were expressed in E. coli strain TOP10 essentially as described (Frangioni and Neel, 1993) . For pull-down experiments 10 cm dishes of (a) con¯uent bEND5 cells pretreated with pervanadate or (b) COS-1 cells transfected with 5 mg of pJFE14-mTie-2, lysed and incubated with 10 mg of GST-fusion protein prebound to glutathion-sepharose as described before (Jallal et al., 1997) . (c) Coimmunoprecipitation of Tie-2 with VE-PTP. COS-1 cells were transfected with FLAG-tagged wt VE-PTP and trapping mutants (C/ S and R/A) together with Tie-2 and immunoprecipitation with Protein A-a-FLAG-AbM2 anity gel (Kodak) were performed. Precipitates were blotted and probed with a-FLAG-AbM2 and after stripping reprobed with an a-Tie-2 speci®c Ab (Santa Cruz) or a-phosphotyrosine speci®c Ab. Methods: pCMV-FLAG VE-PTP wt, C/S and R/A contain cDNA sequences coding for a polypeptide stretch corresponding to aa 1418-1997 in HPTPb cloned into pCMV FLAG-1 (Kodak). Trapping mutations C/S and R/ A were introduced by PCR mutagenesis using primer Prbetamutcs 5'-TCCGTAGTGCACTCGAGTGCTGGTGTG-3' and primer Prbetamutra 5'-GCTGGTGTGGGCGCCACAGGGACGTTC-3'. Transfections: COS-1 cells (Gluzman, 1981) were transfected using the modi®ed calcium phosphate method (Chen and Okayama, 1987) . For transfection 10 mg of pCMV FLAG derivatives and 2 mg of expression plasmids coding for the RTKs were used. As control for transfection eciency 0.5 mg of EGFP expression plasmid (Clontech) were co-transfected. Cells were harvested 2 days after transfection. Transfection rates was evaluated bȳ uorescence microscopy light and was between 30 ± 70% compared to vector control (Figure 5a ). No signi®cant changes were detected in the phosphorylation status of VEGFR-2, irrespective of the presence of VE-PTP or its trapping mutants (Figure 5b ). These ®ndings clearly show that Tie-2 is speci®cally dephosphorylated in the presence of wt VE-PTP and suggest it as a substrate for the endothelial speci®c tyrosine phosphatase VE-PTP.
While gene targeting studies have demonstrated the essential roles of RTKs and their ligands in the developing vasculature (Carmeliet et al., 1996; Dumont et al., 1994; Ferrara et al., 1996; Fong et al., 1995; Sato et al., 1995; Shalaby et al., 1995; Suri et al., 1996) , the biological functions of PTPs are presently far less understood (Neel and Tonks, 1997; Streuli, 1996) . This is the ®rst identi®cation of a receptor-type PTP speci®cally expressed in ECs. Both, Tie-2 (Schlaeger, 1998) and HPTPb, the human homologue of VE-PTP are upregulated with increasing cell density in cultured EC (Gaits et al., 1995) , which in the case of HPTPb is thought to play a role in contact inhibition of growth (Schaapveld et al., 1997) . In vivo, this is paralleled by the predominant expression of VE-PTP in ECs of more mature vessels. In functional experiments we have focused on the analysis of possible physical and enzymatic interactions between VE-PTP and the RTKs Tie-2 and VEGFR-2, because signaling competence of the stronger kinases Tie-2 and VEGFR-2 is at present much better established than that of Tie-1 and VEGFR-1 (Flt-1) . VE-PTP, Tie-2 (SchnuÈ rch and and VEGFR-2 are co-expressed in embryonic development, however, our biochemical analysis suggests that VE-PTP serves to attenuate only Tie-2 activity. The Angiopoietin/Tie-2 system has been shown to be important for sprouting angiogenesis and vascular remodeling both, in vivo (Maisonpierre et al., 1997; Sato et al., 1995; Suri et al., 1996) and in vitro (Asahara et al., 1998; Koblizek et al., 1998; Witzenbichler et al., 1998 ). An activating mutation in the catalytic domain of Tie-2 causes inherited venous malformations (VM) (Vikkula et al., 1996) . Since inactivating mutations of VE-PTP could lead to persisting Tie-2 activity, the VE-PTP gene is an obvious candidate locus for similar vascular abnormalities. Impaired recruitment of smooth muscle cells (SMCs) to ECs in VM suggests an involvement of Tie-2 activity in the crosstalk of both cell types. Furthermore, the structure of the extracellular domain of subclass III RPTPs such as VE-PTP, suggests roles as adhesion receptors (Brady-Kalnay and Tonks, 1995) or in the recognition of ECM molecules. Homophilic interaction of VE-PTP molecules on neighboring ECs or binding of VE-PTP to yet unidenti®ed ligands expressed by the adjacent SMCs could modulate Tie-2 activity and thereby regulate blood vessel formation or maturation. Future studies toward the identi®cation of potential ligands of VE-PTP will help to clarify its biological activity. Finally, only conditional mutagenesis in vivo following gene targeting promises to fully elucidate the functional interdependence of Tie-2 and VE-PTP. Figure 5 Dephosphorylation of (a) Tie-2 but not (b) VEGFR-2 by wt VE-PTP. RTKs were immunoprecipitated from cotransfected COS-1 cells with speci®c mAbs and precipitates blotted with a-phosphotyrosine speci®c Ab and after stripping reprobed with RTK-speci®c Abs. Methods: Published Tie-2 and VEGFR-2 expression vectors (Koblizek et al., 1997; Millauer et al., 1993) and rat monoclonal antibodies (mAb) against Tie-2 (3g1 and 4g8) (Koblizek et al., 1997) and Flk-1 (12a1) (Kataoka et al., 1997) were used. IPs were performed with 5 mg of the mAbs and immunoblotting was done with 2 mg/ml. Polyclonal aFlk-1 antiserum 1D3 (SUGEN) was used at a 1 : 5000 dilution. a-FLAG-Ab M2 (Kodak), polyclonal antiserum against Tie-2 (Santa Cruz Biotechnology) and mouse mAb a-phosphotyrosineAb PY20 (Transduction Labs) were used according to the manufacturer's instructions. Immunoprecipitations and immunoblotting were performed as described previously (Esser et al., 1998; Jallal et al., 1997) 
